HOME >> BIOLOGY >> NEWS
Mount Sinai School of Medicine conducting clinical trials with gene therapy for colorectal cancer

Researchers at Mount Sinai School of Medicine began clinical trials on a unique and promising approach to gene therapy for colorectal cancer. The study uses genes to make the cancer cells look foreign to the body's immune system, which will then attack and destroy the cancer.

Colorectal cancer is the second leading cancer killer in the United States. The American Cancer Society estimates that 147,500 cases of colorectal cancer will be diagnosed in the country in 2003 and 57,000 people will die from the disease.

In experiments with laboratory animals, Mount Sinai researchers have demonstrated that their approach to gene therapy, known as tumor immunization, extended life in all animals tested and wiped out cancer entirely in up to 20% of animals whose cancer had spread from the colon to the liver.

"Cancer cells are able to grow unimpeded by the body's defenses because they look very similar to healthy cells, with only very subtle differences that pass under the radar screen of the body's immune cells," said Savio Woo, PhD, Director of the Carl C. Icahn Center for Gene Therapy and Molecular Medicine at Mount Sinai School of Medicine. "We use gene transfer technology to insert a gene into the cancer cells that makes them visible to the body's natural immune defenses."

The method of tumor immunization which Mount Sinai researchers developed involves transferring a gene that codes for Interleukin-12 (IL12) into cancer cells directly in the patient's tumor. IL12 is a protein that is not normally produced by cancer cells. When the cancer cells produce this protein as a result of gene transfer it acts as a signal to a special class of white blood cells of the immune system telling them, "These cancer cells are dangerous. Come over here and destroy them."

The laboratory and animal studies conducted by Dr. Woo and colleagues have provided evidence that delivering the IL12 gene to cancer cells can trigger a targeted immune response that destroy
'"/>

Contact: Debra Kaplan
debra.kaplan@mssm.edu
212-659-9045
The Mount Sinai Hospital / Mount Sinai School of Medicine
21-Jan-2004


Page: 1 2

Related biology news :

1. Mount Holyoke College series examines advances in human reproductive technologies
2. Mountain cloud forests imperiled by lowland deforestation, says Science study
3. Yale researchers solve structure of the ribosome: groundbreaking achievement like climbing Mount Everest
4. Cadmium toxicity threatening wildlife in Rocky Mountains
5. Extra oxygen improves survival odds for climbers on Mount Everest, K2
6. Biological legacies a key of ecological rebirth after Mount St. Helens eruption
7. Mountains of variables: The effect of landscape features on atmospheric deposition
8. Chytrid fungus associated with boreal toad deaths in Rocky Mountains
9. Mountain Lake Hotel places environmental book in rooms
10. USGS Study Confirms An Urban Air-Pollution Problem At Mount Rainier National Park
11. Evidence Mounts Against Maintstream Dogma In Embryology, Could Shed New Light On Neurological Defects

Post Your Comments:
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: